ES2044840T3 - Composiciones estabilizadas del activador del plasminogeno de tejido humano. - Google Patents

Composiciones estabilizadas del activador del plasminogeno de tejido humano.

Info

Publication number
ES2044840T3
ES2044840T3 ES86309811T ES86309811T ES2044840T3 ES 2044840 T3 ES2044840 T3 ES 2044840T3 ES 86309811 T ES86309811 T ES 86309811T ES 86309811 T ES86309811 T ES 86309811T ES 2044840 T3 ES2044840 T3 ES 2044840T3
Authority
ES
Spain
Prior art keywords
plasminogen activator
human tissue
tissue plasminogen
stabilized compositions
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86309811T
Other languages
English (en)
Inventor
William Franklin Bennett
Larry Alan Gatlin
Stuart Elliot Builder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2044840(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2044840T3 publication Critical patent/ES2044840T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIONES ACEPTABLES FARMACEUTICAMENTE ESTABLES QUE CONTIENEN CARACTERISTICAS DE TEJIDO ACTIVADOR PLASMINOGENO HUMANO, POR EJEMPLO, UN ION ARGININIUM CONTENIENDO UN NIVEL DE UN COMPONENTE.
ES86309811T 1985-12-17 1986-12-16 Composiciones estabilizadas del activador del plasminogeno de tejido humano. Expired - Lifetime ES2044840T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (1)

Publication Number Publication Date
ES2044840T3 true ES2044840T3 (es) 1994-01-16

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86309811T Expired - Lifetime ES2044840T3 (es) 1985-12-17 1986-12-16 Composiciones estabilizadas del activador del plasminogeno de tejido humano.

Country Status (23)

Country Link
US (2) US4777043A (es)
EP (1) EP0228862B1 (es)
JP (2) JPH0714886B2 (es)
KR (1) KR950010322B1 (es)
AT (1) ATE79273T1 (es)
AU (1) AU600246B2 (es)
DD (1) DD255477A5 (es)
DE (2) DE3686410T2 (es)
DK (1) DK174203B1 (es)
ES (1) ES2044840T3 (es)
FI (1) FI88873C (es)
FR (1) FR2591485B1 (es)
GB (1) GB2184354B (es)
GR (1) GR3006078T3 (es)
HU (1) HU200101B (es)
IE (1) IE59060B1 (es)
IL (1) IL80904A (es)
MY (1) MY102185A (es)
NO (1) NO168988C (es)
NZ (1) NZ218612A (es)
PH (1) PH24716A (es)
PT (1) PT83933B (es)
ZA (1) ZA869457B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
JP2003507388A (ja) * 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
CA2384756C (en) * 1999-11-04 2010-09-28 Genentech, Inc. Reversed-phase hplc assay for plasminogen activators
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
JP6649246B2 (ja) * 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU596356B2 (en) * 1985-04-22 1990-05-03 Genentech Inc. Novel human tissue plasminogen activator mutants
NO171344C (no) * 1985-05-28 1993-03-03 Wellcome Found Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
DD255477A5 (de) 1988-04-06
KR870005647A (ko) 1987-07-06
DE3642960A1 (de) 1987-06-19
FR2591485B1 (fr) 1989-07-28
AU6661086A (en) 1987-06-18
AU600246B2 (en) 1990-08-09
IL80904A0 (en) 1987-03-31
PT83933B (pt) 1989-01-17
JPH0714886B2 (ja) 1995-02-22
EP0228862A3 (en) 1988-09-28
DE3686410T2 (de) 1993-02-18
EP0228862B1 (en) 1992-08-12
DK174203B1 (da) 2002-09-16
GB2184354B (en) 1990-04-11
DK605786D0 (da) 1986-12-16
ATE79273T1 (de) 1992-08-15
IE59060B1 (en) 1993-12-15
NZ218612A (en) 1989-07-27
FI88873B (fi) 1993-04-15
US4908205A (en) 1990-03-13
FI865159L (fi) 1987-06-18
JPH07173076A (ja) 1995-07-11
US4777043A (en) 1988-10-11
MY102185A (en) 1992-04-30
ZA869457B (en) 1988-08-31
GB2184354A (en) 1987-06-24
PT83933A (en) 1987-01-01
DE3686410D1 (de) 1992-09-17
IL80904A (en) 1992-01-15
GB8629981D0 (en) 1987-01-28
FI88873C (fi) 1993-07-26
PH24716A (en) 1990-10-01
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
NO168988C (no) 1992-04-29
HU200101B (en) 1990-04-28
EP0228862A2 (en) 1987-07-15
NO168988B (no) 1992-01-20
FR2591485A1 (fr) 1987-06-19
GR3006078T3 (es) 1993-06-21
KR950010322B1 (ko) 1995-09-14
FI865159A0 (fi) 1986-12-17
DK605786A (da) 1987-06-18
JPS62164632A (ja) 1987-07-21
NO865079L (no) 1987-06-18
NO865079D0 (no) 1986-12-16

Similar Documents

Publication Publication Date Title
GB2184354B (en) Stabilized human tissue plasminogen activator compositions
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
ES2114487B1 (es) Mezcla estabilizante sinergistica.
DK261490D0 (da) New pharmaceutical compound
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2054944T3 (es) Bis-(tri-t-alquilfenoxi) difosfaespiroundecanos.
IT1249047B (it) Composizione farmaceutica per il trattamento della cataratta
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
NO872875L (no) Modifisert vevsplasminaktivator, samt fremgangsmŸte for fremstilling av en slik.
ES2042553T3 (es) Un proceso para la preparacion de un activador del plasminogeno fibrinoliticamente activo.
ES2076248T3 (es) Dibenzofuranos substituidos y metodos para el uso de los mismos.
DK630088D0 (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
TR22867A (tr) Birden fazla aktif bilesen ihtiva eden insektisid terkibi
SE8802040D0 (sv) New use
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
JPS55147220A (en) Hemostatic and thrombocyte number increaser comprising alpha,beta-diaminopropionic acid
ATE67674T1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.
SE8704049D0 (sv) Novel pharmacological compounds
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
DK98788A (da) Benzylaminoaryl-dihydropyridinlactoner, fremgangmsaade til deres fremstilling samt deres anvendelse som laegemidler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 228862

Country of ref document: ES